Trial Profile

A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab Relative to Apixaban on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients With Cancer Associated VTE

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 11 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abelacimab (Primary) ; Abelacimab (Primary) ; Apixaban
Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
Focus Registrational; Therapeutic Use
Acronyms ASTER
Sponsors Anthos Therapeutics

23 Feb 2026 Status changed from active, no longer recruiting to discontinued.
22 Jan 2026 Planned End Date changed from 31 Dec 2026 to 28 Feb 2027.
22 Jan 2026 Planned End Date changed from 1 Feb 2027 to 31 Dec 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com